Ami Organics Valoración
¿Está AMIORG infravalorada en comparación con su valor justo, las previsiones de los analistas y su precio en relación con el mercado?
Puntuación valoración
0/6Puntuación valoración 0/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. Similares
Price-To-Earnings vs. Industria
Price-To-Earnings vs. Ratio justo
Pronóstico de los analistas
Precio de la acción vs. Valor justo
¿Cuál es el precio justo de AMIORG si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.
Por debajo del valor justo: AMIORG (₹1972.45) is trading above our estimate of fair value (₹692.42)
Muy por debajo del valor justo: AMIORG is trading above our estimate of fair value.
Métrica de valoración clave
¿Cuál es la mejor métrica para la valoración relativa de AMIORG?
Otras métricas financieras que pueden ser útiles para la valoración relativa.
¿Cual es el ratio n/a de AMIORG? | |
---|---|
n/a | 0x |
n/a | n/a |
Capitalización bursátil | ₹80.74b |
Estadísticas clave | |
---|---|
Valor empresa-ingresos | 9.5x |
Valor empresarial/EBITDA | 50.6x |
Ratio precio-expectativas de beneficios | 2.1x |
Ratio Precio-beneficio vs. Similares
¿Cómo se compara ratio PE de AMIORG con sus similares?
Empresa | Precio-beneficio futuro | Crecimiento estimado | Capitalización de mercado |
---|---|---|---|
Promedio de empresas similares | 73.3x | ||
ORCHPHARMA Orchid Pharma | 62.9x | 43.7% | ₹70.5b |
531599 FDC | 27.8x | n/a | ₹87.4b |
500126 Procter & Gamble Health | 43.6x | n/a | ₹87.6b |
530549 Shilpa Medicare | 158.8x | 71.2% | ₹71.1b |
AMIORG Ami Organics | 86.7x | 42.1% | ₹80.7b |
Price-To-Earnings vs. Similares: AMIORG is expensive based on its Price-To-Earnings Ratio (86.7x) compared to the peer average (73.3x).
Ratio Precio-beneficio vs. Industria
¿Cómo se compara el ratio PE de AMIORG con el de otras empresas de la industria IN Pharmaceuticals ?
Price-To-Earnings vs. Industria: AMIORG is expensive based on its Price-To-Earnings Ratio (86.7x) compared to the Indian Pharmaceuticals industry average (38.3x).
Ratio Precio-beneficio vs. Ratio justo
¿Cuál es el ratio PE de AMIORG comparado con su ratio PE justo? Es el ratio PE esperado teniendo en cuenta las estimaciones de crecimiento de los ingresos de la empresa, los márgenes de ganancias y otros factores de riesgo.
Ratio justo | |
---|---|
Ratio PE actual | 86.7x |
Ratio PE justo | 52.5x |
Price-To-Earnings vs. Ratio justo: AMIORG is expensive based on its Price-To-Earnings Ratio (86.7x) compared to the estimated Fair Price-To-Earnings Ratio (52.5x).
Precio objetivo de los analistas
¿Cuál es la estimación de los analistas a 12 meses, y existe una confianza estadística en el precio objetivo de consenso?
Fecha | Precio de las acciones | Precio objetivo promedio a 1 año | Dispersión | Alto | Bajo | Precio real 1 año | Analistas |
---|---|---|---|---|---|---|---|
Actual | ₹1,972.45 | ₹2,129.20 +7.9% | 10.6% | ₹2,500.00 | ₹1,847.00 | n/a | 5 |
Oct ’25 | ₹1,720.00 | ₹1,599.80 -7.0% | 16.6% | ₹1,965.00 | ₹1,250.00 | n/a | 5 |
Sep ’25 | ₹1,381.05 | ₹1,508.50 +9.2% | 14.2% | ₹1,810.00 | ₹1,250.00 | n/a | 4 |
Aug ’25 | ₹1,350.15 | ₹1,414.75 +4.8% | 14.7% | ₹1,750.00 | ₹1,200.00 | n/a | 4 |
Jul ’25 | ₹1,317.90 | ₹1,392.25 +5.6% | 12.4% | ₹1,660.00 | ₹1,200.00 | n/a | 4 |
Jun ’25 | ₹1,217.25 | ₹1,392.25 +14.4% | 12.4% | ₹1,660.00 | ₹1,200.00 | n/a | 4 |
May ’25 | ₹1,230.85 | ₹1,324.75 +7.6% | 15.3% | ₹1,660.00 | ₹1,134.00 | n/a | 4 |
Apr ’25 | ₹1,113.95 | ₹1,273.75 +14.3% | 13.1% | ₹1,560.00 | ₹1,134.00 | n/a | 4 |
Mar ’25 | ₹1,118.35 | ₹1,273.75 +13.9% | 13.1% | ₹1,560.00 | ₹1,134.00 | n/a | 4 |
Feb ’25 | ₹1,137.85 | ₹1,416.25 +24.5% | 8.5% | ₹1,560.00 | ₹1,225.00 | n/a | 4 |
Jan ’25 | ₹1,144.35 | ₹1,378.75 +20.5% | 9.3% | ₹1,560.00 | ₹1,225.00 | n/a | 4 |
Dec ’24 | ₹1,100.80 | ₹1,378.75 +25.2% | 9.3% | ₹1,560.00 | ₹1,225.00 | n/a | 4 |
Nov ’24 | ₹1,158.75 | ₹1,463.25 +26.3% | 7.1% | ₹1,630.00 | ₹1,343.00 | ₹1,971.50 | 4 |
Oct ’24 | ₹1,233.25 | ₹1,453.75 +17.9% | 8.0% | ₹1,630.00 | ₹1,305.00 | ₹1,720.00 | 4 |
Sep ’24 | ₹1,315.95 | ₹1,453.75 +10.5% | 8.0% | ₹1,630.00 | ₹1,305.00 | ₹1,381.05 | 4 |
Aug ’24 | ₹1,153.25 | ₹1,416.25 +22.8% | 9.1% | ₹1,630.00 | ₹1,305.00 | ₹1,350.15 | 4 |
Jul ’24 | ₹1,272.20 | ₹1,421.67 +11.7% | 10.4% | ₹1,630.00 | ₹1,305.00 | ₹1,317.90 | 3 |
Jun ’24 | ₹1,209.20 | ₹1,421.67 +17.6% | 10.4% | ₹1,630.00 | ₹1,305.00 | ₹1,217.25 | 3 |
May ’24 | ₹1,066.30 | ₹1,346.33 +26.3% | 6.7% | ₹1,450.00 | ₹1,229.00 | ₹1,230.85 | 3 |
Apr ’24 | ₹889.70 | ₹1,346.33 +51.3% | 6.7% | ₹1,450.00 | ₹1,229.00 | ₹1,113.95 | 3 |
Mar ’24 | ₹907.10 | ₹1,346.33 +48.4% | 6.7% | ₹1,450.00 | ₹1,229.00 | ₹1,118.35 | 3 |
Feb ’24 | ₹865.70 | ₹1,416.33 +63.6% | 11.6% | ₹1,630.00 | ₹1,229.00 | ₹1,137.85 | 3 |
Jan ’24 | ₹965.35 | ₹1,416.33 +46.7% | 11.6% | ₹1,630.00 | ₹1,229.00 | ₹1,144.35 | 3 |
Dec ’23 | ₹994.50 | ₹1,416.33 +42.4% | 11.6% | ₹1,630.00 | ₹1,229.00 | ₹1,100.80 | 3 |
Nov ’23 | ₹944.70 | ₹1,394.67 +47.6% | 12.3% | ₹1,630.00 | ₹1,229.00 | ₹1,158.75 | 3 |
Pronóstico de los analistas: Target price is less than 20% higher than the current share price.